News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,063 Results
Type
Article (38990)
Company Profile (277)
Press Release (644796)
Section
Business (203839)
Career Advice (1987)
Deals (35359)
Drug Delivery (84)
Drug Development (80772)
Employer Resources (168)
FDA (16085)
Job Trends (14800)
News (344486)
Policy (32431)
Tag
Academia (2530)
Alliances (49041)
Alzheimer's disease (1218)
Approvals (16005)
Artificial intelligence (122)
Bankruptcy (352)
Best Places to Work (11489)
Biotechnology (196)
Breast cancer (111)
Cancer (968)
Cardiovascular disease (82)
Career advice (1657)
Cell therapy (209)
Clinical research (63999)
Collaboration (339)
Compensation (173)
COVID-19 (2523)
C-suite (85)
Data (940)
Diabetes (140)
Diagnostics (6113)
Earnings (84489)
Employer resources (146)
Events (109114)
Executive appointments (256)
FDA (16550)
Funding (301)
Gene therapy (153)
GLP-1 (566)
Government (4320)
Healthcare (18660)
Infectious disease (2602)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16276)
Job creations (3623)
Job search strategy (1415)
Layoffs (409)
Legal (7849)
Lung cancer (158)
Manufacturing (159)
Medical device (13152)
Medtech (13157)
Mergers & acquisitions (19120)
Metabolic disorders (375)
Neuroscience (1462)
NextGen Class of 2024 (6497)
Non-profit (4463)
Northern California (1304)
Obesity (223)
Opinion (176)
Patents (96)
People (56159)
Phase I (19867)
Phase II (28178)
Phase III (21032)
Pipeline (320)
Postmarket research (2553)
Preclinical (8452)
Radiopharmaceuticals (234)
Rare diseases (189)
Real estate (5888)
Regulatory (21460)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1163)
Startups (3560)
United States (12285)
Vaccines (541)
Weight loss (163)
Date
Today (232)
Last 7 days (1068)
Last 30 days (3276)
Last 365 days (35457)
2024 (31169)
2023 (40074)
2022 (51174)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (188)
Asia (37044)
Australia (6040)
California (2936)
Canada (1207)
China (224)
Colorado (127)
Connecticut (131)
Europe (79307)
Florida (415)
Georgia (104)
Illinois (320)
Indiana (187)
Kansas (96)
Maryland (543)
Massachusetts (2374)
Michigan (146)
Minnesota (257)
New Jersey (868)
New York (876)
North Carolina (674)
Northern California (1304)
Ohio (129)
Pennsylvania (780)
South America (1091)
Southern California (1163)
Texas (404)
Utah (84)
Washington State (335)
684,063 Results for "alumis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Alumis Announces Pricing of Initial Public Offering - June 28, 2024
Alumis Inc. announced the pricing of its initial public offering of 13,125,000 shares of common stock at an initial public offering price of $16.00 per share.
June 28, 2024
·
6 min read
Press Releases
Alumis to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 4, 2024
·
2 min read
Deals
Alumis Pushes Through With Smaller IPO, Looks to Raise $250M for Immuno Candidate
Alumis is debuting in an initial public offering Friday on the Nasdaq, though the $250 million IPO is less than its initial targeted raise of $274 million just days ago.
June 28, 2024
·
2 min read
·
Tristan Manalac
Business
Alumis to Participate in Upcoming September Investor Conferences
September 3, 2024
·
2 min read
Deals
Alumis Files for IPO to Fund Phase III Trials of Potential Rival Drug to BMS’ Sotyktu
In an SEC filing on Friday, Alumis said it aims to start late-stage trials of a TYK2 inhibitor in plaque psoriasis this year and is seeking public funding for the studies.
June 10, 2024
·
2 min read
·
Nick Paul Taylor
Drug Development
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.
April 30, 2024
·
3 min read
Biotech Bay
Alumis to Participate in the 2024 Leerink Partners Global Biopharma Conference
Alumis Inc. today announced that Company management will host investor meetings at the 2024 Leerink Partners Global Biopharma Conference on March 12, 2024, in Miami, Florida.
March 11, 2024
·
1 min read
Drug Development
Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced preclinical data for A-005 at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum.
March 1, 2024
·
2 min read
Business
Alumis Announces Pricing of Initial Public Offering
July 2, 2024
·
6 min read
Biotech Bay
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced an upsized $259M Series C financing.
March 6, 2024
·
7 min read
1 of 68,407
Next
